Canada presents interesting current HTA-insights. Here are the outcomes compiled by MORSE Consulting.

 

Highlights:

🏛️ In Q2 2025, CDA-AMC issued 21 final recommendations, an increase from the 16 issued in Q1.

⏳️ CDA-AMC issued its 2nd ever time-limited recommendation (TLR), which has successfully concluded negotiation with pan-Canadian Pharmaceutical Alliance (pCPA) in April 2025.

 

The stats:

✅ 18 Conditional reimbursement

⏳️ 1 Time-limited reimbursement

❌ 2 Not-reimbursed

 

📝 Register here to receive the latest and upcoming issues of the complete #AccessBriefing with HTA insights from 14 countries, compiled by 9 partners of our network 👉 https://forms.office.com/e/Jt8bPmVkdJ